Skye Bioscience (SKYE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.55, -2.52% vs the prior close of $1.59.
- Volume 19.62K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SKYE dips 2.5% to $1.55. Closed at $1.55, -2.52% vs the prior close of $1.59. Day range $1.54–$1.60, opened at $1.60.
SKYE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SKYE dips 2.5% to $1.55
- Closed at $1.55, -2.52% vs the prior close of $1.59. Day range $1.54–$1.60, opened at $1.60.
- Volume was 19.62K shares, 0.2x its 50-day average of 110.63K — lighter than usual.
- Price is -28.1% vs its 50-day average ($2.16) and -70.0% vs its 200-day average ($5.17).
- 52-week range $1.50–$13.28; today's close sits at 0% of that range, 88.3% below the 52-week high.
Oct 15, 2026 — SKYE rises 1.3% to $1.59
- Closed at $1.59, +1.27% vs the prior close of $1.57. Day range $1.55–$1.65, opened at $1.60.
- Volume was 17.50K shares, 0.2x its 50-day average of 110.55K — lighter than usual.
- Price is -27.7% vs its 50-day average ($2.20) and -69.4% vs its 200-day average ($5.19).
- 52-week range $1.50–$13.28; today's close sits at 1% of that range, 88.0% below the 52-week high.
Oct 14, 2026 — SKYE rises 2.6% to $1.57
- Closed at $1.57, +2.61% vs the prior close of $1.53. Day range $1.50–$1.60, opened at $1.53.
- Volume was 36.80K shares, 0.3x its 50-day average of 110.24K — lighter than usual.
- Price is -30.5% vs its 50-day average ($2.26) and -69.9% vs its 200-day average ($5.21).
- 52-week range $1.50–$13.28; today's close sits at 1% of that range, 88.2% below the 52-week high.
Oct 13, 2026 — SKYE slides 3.2% to $1.53, a 52-week low
- Closed at $1.53, -3.16% vs the prior close of $1.58. Day range $1.50–$1.65, opened at $1.65.
- Volume was 28.60K shares, 0.3x its 50-day average of 109.92K — lighter than usual.
- Price is -34.0% vs its 50-day average ($2.32) and -70.8% vs its 200-day average ($5.24).
- 52-week range $1.50–$13.60; today's close sits at 0% of that range, 88.8% below the 52-week high.
Oct 12, 2026 — SKYE slides 6.5% to $1.58
- Closed at $1.58, -6.51% vs the prior close of $1.69. Day range $1.55–$1.70, opened at $1.67.
- Volume was 42.40K shares, 0.4x its 50-day average of 109.48K — lighter than usual.
- Price is -33.7% vs its 50-day average ($2.38) and -70.0% vs its 200-day average ($5.26).
- 52-week range $1.50–$14.08; today's close sits at 1% of that range, 88.8% below the 52-week high.
Oct 9, 2026 — SKYE rises 0.6% to $1.69, 3 up days in a row
- Closed at $1.69, +0.60% vs the prior close of $1.68. Day range $1.67–$1.77, opened at $1.69.
- Volume was 18.70K shares, 0.2x its 50-day average of 109.62K — lighter than usual.
- Price is -30.8% vs its 50-day average ($2.44) and -68.0% vs its 200-day average ($5.29).
- 52-week range $1.50–$14.08; today's close sits at 2% of that range, 88.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — SKYE rises 1.8% to $1.68
- Closed at $1.68, +1.82% vs the prior close of $1.65. Day range $1.62–$1.69, opened at $1.66.
- Volume was 21.30K shares, 0.2x its 50-day average of 109.43K — lighter than usual.
- Price is -32.8% vs its 50-day average ($2.50) and -68.4% vs its 200-day average ($5.32).
- 52-week range $1.50–$14.51; today's close sits at 1% of that range, 88.4% below the 52-week high.
Oct 7, 2026 — SKYE rises 1.9% to $1.65
- Closed at $1.65, +1.85% vs the prior close of $1.62. Day range $1.62–$1.75, opened at $1.62.
- Volume was 55.70K shares, 0.5x its 50-day average of 108.80K — lighter than usual.
- Price is -35.7% vs its 50-day average ($2.57) and -69.1% vs its 200-day average ($5.34).
- 52-week range $1.50–$16.80; today's close sits at 1% of that range, 90.2% below the 52-week high.
Oct 6, 2026 — SKYE slides 6.4% to $1.62
- Closed at $1.62, -6.36% vs the prior close of $1.73. Day range $1.62–$1.77, opened at $1.74.
- Volume was 30.80K shares, 0.3x its 50-day average of 108.52K — lighter than usual.
- Price is -38.4% vs its 50-day average ($2.63) and -69.9% vs its 200-day average ($5.38).
- 52-week range $1.50–$18.40; today's close sits at 1% of that range, 91.2% below the 52-week high.
Oct 5, 2026 — SKYE rises 3.0% to $1.73
- Closed at $1.73, +2.98% vs the prior close of $1.68. Day range $1.65–$1.75, opened at $1.65.
- Volume was 35.20K shares, 0.3x its 50-day average of 107.93K — lighter than usual.
- Price is -35.9% vs its 50-day average ($2.70) and -68.0% vs its 200-day average ($5.41).
- 52-week range $1.50–$39.92; today's close sits at 1% of that range, 95.7% below the 52-week high.
Oct 2, 2026 — SKYE jumps 5.0% to $1.68
- Closed at $1.68, +5.00% vs the prior close of $1.60. Day range $1.58–$1.68, opened at $1.64.
- Volume was 11.10K shares, 0.1x its 50-day average of 107.90K — lighter than usual.
- Price is -39.3% vs its 50-day average ($2.77) and -69.2% vs its 200-day average ($5.45).
- 52-week range $1.50–$39.92; today's close sits at 0% of that range, 95.8% below the 52-week high.
SKYE latest news & SEC filings
Every SEC filing by or about SKYE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schwab Andrew J. sold 27,612 shares at $1.65 (≈$45.56K) on Sep 22, 2026; now holds 114,851
- Schwab Andrew J. sold 1,088 shares at $1.65 (≈$1.80K) on Sep 22, 2026; now holds 4,528
- Schwab Andrew J. sold 114,851 shares at $1.61 (≈$184.91K) on Sep 23, 2026
- Schwab Andrew J. sold 4,528 shares at $1.61 (≈$7.29K) on Sep 23, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 27,612 shares at $1.65 (≈$45.56K) on Sep 22, 2026; now holds 114,851
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 1,088 shares at $1.65 (≈$1.80K) on Sep 22, 2026; now holds 4,528
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 114,851 shares at $1.61 (≈$184.91K) on Sep 23, 2026
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 4,528 shares at $1.61 (≈$7.29K) on Sep 23, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schwab Andrew J. sold 32,607 shares at $1.91 (≈$62.28K) on Sep 16, 2026; now holds 142,463
- Schwab Andrew J. sold 1,285 shares at $1.91 (≈$2.45K) on Sep 16, 2026; now holds 5,616
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 32,607 shares at $1.91 (≈$62.28K) on Sep 16, 2026; now holds 142,463
- 5Am Partners Vii, Llc & 5Am Ventures Vii, L.P. & 5Am Partners Ii, Llc & 5Am Ventures Ii Lp & 5Am Co-Investors Ii Lp & Diekman John D & Parmar Kush & Rocklage Scott M sold 1,285 shares at $1.91 (≈$2.45K) on Sep 16, 2026; now holds 5,616
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Aug 24, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 20, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 20, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 3.03 — Change to shareholder rights.
Aug 19, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Things to know before you trade SKYE
- Last results release: Mar 10, 2026 (8-K Item 2.02). Previous ones: Nov 10, 2025, Aug 7, 2025, May 8, 2025. Based on that rhythm, the next report is likely around Jun 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.94% (largest 6.5%).
- Liquidity: about 48.71K shares (≈$75.50K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.55 vs a range of $1.50–$13.28 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:8 on Aug 24, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Andrew J. Schwab sold 4,528 shares on Sep 23, 2026.
- Latest filings: 8-K Sep 11, 2026; 8-K Aug 24, 2026; 8-K Aug 19, 2026.
- Share count: 35.42M shares outstanding (Aug 10, 2026), +14.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SKYE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.60 | 1.60 | 1.54 | 1.55 | 19.62K |
| Oct 15, 2026 | 1.60 | 1.65 | 1.55 | 1.59 | 17.50K |
| Oct 14, 2026 | 1.53 | 1.60 | 1.50 | 1.57 | 36.80K |
| Oct 13, 2026 | 1.65 | 1.65 | 1.50 | 1.53 | 28.60K |
| Oct 12, 2026 | 1.67 | 1.70 | 1.55 | 1.58 | 42.40K |
| Oct 9, 2026 | 1.69 | 1.77 | 1.67 | 1.69 | 18.70K |
| Oct 8, 2026 | 1.66 | 1.69 | 1.62 | 1.68 | 21.30K |
| Oct 7, 2026 | 1.62 | 1.75 | 1.62 | 1.65 | 55.70K |
| Oct 6, 2026 | 1.74 | 1.77 | 1.62 | 1.62 | 30.80K |
| Oct 5, 2026 | 1.65 | 1.75 | 1.65 | 1.73 | 35.20K |
| Oct 2, 2026 | 1.64 | 1.68 | 1.58 | 1.68 | 11.10K |
| Oct 1, 2026 | 1.61 | 1.64 | 1.55 | 1.60 | 20.20K |
| Sep 30, 2026 | 1.59 | 1.72 | 1.57 | 1.61 | 72.40K |
| Sep 29, 2026 | 1.64 | 1.64 | 1.56 | 1.59 | 48.40K |
| Sep 28, 2026 | 1.70 | 1.70 | 1.53 | 1.61 | 51.00K |
| Sep 25, 2026 | 1.76 | 1.76 | 1.59 | 1.67 | 43.20K |
| Sep 24, 2026 | 1.80 | 1.87 | 1.70 | 1.70 | 37.40K |
| Sep 23, 2026 | 1.74 | 1.95 | 1.60 | 1.80 | 217.70K |
| Sep 22, 2026 | 1.78 | 1.81 | 1.62 | 1.71 | 93.70K |
| Sep 21, 2026 | 1.80 | 1.85 | 1.72 | 1.78 | 72.50K |
About Skye Bioscience
Skye Bioscience (SKYE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1516551.
SKYE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Deborah H. Charych | Director | Apr 2, 2026 |
| Punit Dhillon | Chief Executive Officer | Aug 7, 2026 |
| Paul A. Grayson | Director | Apr 2, 2026 |
| Annalisa Jenkins | Director | Apr 2, 2026 |
| Andrew J. Schwab | Director | Sep 24, 2026 |
| Karen L. Smith | Director | Apr 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kaitlyn Arsenault | Chief Financial Officer | Feb 9, 2026 |
| Puneet S. Arora | Chief Medical Officer | Feb 9, 2026 |
| Punit Dhillon | Chief Executive Officer | Aug 7, 2026 |
| Tuan Tu Diep | Chief Operating Officer | Apr 2, 2026 |
| John P Sharp | Chief Financial Officer | Apr 28, 2026 |
| Christopher Twitty | Chief Scientific Officer | Apr 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 23, 2026 | Andrew J. Schwab | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Andrew J. Schwab | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Ventures Ii Lp 5Am | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Ventures Ii Lp 5Am | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Ventures Ii Lp 5Am | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Ventures Ii Lp 5Am | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Partners Vii, Llc 5Am | Sale | 4,528 | $1.61 |
| Sep 23, 2026 | Partners Vii, Llc 5Am | Sale | 114,851 | $1.61 |
| Sep 23, 2026 | Partners Vii, Llc 5Am | Sale | 4,528 | $1.61 |
SKYE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-55.92M | -1.41 | $-43.06M |
| Dec 31, 2024 | — | $-26.57M | -0.73 | $-25.24M |
| Dec 31, 2023 | — | $-37.64M | -5.37 | $-13.95M |
| Dec 31, 2022 | — | $-19.48M | -8.77 | $-12.74M |
| Dec 31, 2021 | — | $-8.52M | -0.02 | $-6.47M |
Latest balance sheet: total assets $11.03M, total liabilities $11.53M, cash $8.07M (as of Jun 30, 2026).
SKYE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 10, 2026 | 8-K Item 2.02 (results) | $6.39 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $11.36 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $28.40 |
| May 8, 2025 | 8-K Item 2.02 (results) | $14.32 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $15.12 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $43.52 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SKYE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.